Lyxumia (lixisenatide)
- Region
- 🇪🇺 EU
- Active substance
- lixisenatide
- Company
- Sanofi Winthrop Industrie
- Status
- Withdrawn
- Therapeutic area
- Diabetes Mellitus, Type 2
- CHMP opinion
- Thu 15 Nov 2012
- EU approval
- Thu 31 Jan 2013
- Application
- EMEA/H/C/002445
- ATC
- A10BJ03
- Official record
- www.ema.europa.eu
Indication
Lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Suliqua Authorised · Sanofi Winthrop Industrie
Follow Lyxumia
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.